Dendritic cells (DC), considered as immunological sentinels of the organism since they are antigen presenting cells, create the link between innate and adaptive immunity. DC include myeloid dendritic cells (MDC) and plasmacytoid dendritic cells (PDC). The presence of PDC, cells capable of producing large quantities of interferon alpha (IFN-α) in response to pathogenic agents or danger signals, seem to be tightly related to pathological conditions. Thereby, PDC have been observed in inflammatory immunoallergic dermatological disorders, in malignant cutaneous tumours and in cutaneous lesions of infectious origin. They seem to play a crucial role in the initiation of the pathological process of autoimmune diseases such as lupus or psoriasis. Their function within a tumour context is not as well known and is controversial. They could have a tolerogenic role towards tumour cells in the absence of activator but they also have the capacity to become activated in response to Toll-like receptor (TLR) ligands and could therefore be usefull for therapeutic purposes.
Introduction
The skin epidermis constitutes the direct interface with the external environment and the first barrier of protection against the penetration into the organism of exogenous pathogenic agents or substances. The underlying dermis, where vascular structures are located, ensures functions of thermoregulation and nutrition. Immune cells are located and moved between the epidermis and the dermis. They are organised in networks and take part in the defence against pathogenic agents. DC are professional antigen presenting cells (APC) capable of capturing and presenting antigens and also initiating and orchestrating the immune response by establishing links between innate and adaptive responses (1) . In a physiological situation two DC contingents of myeloid origin are present in the skin: epidermal Langerhans cells and dermal DC also known as interstitial DC (2) . The presence of PDC in healthy skin is controversial and only one study has shown the presence of rare immature PDC (BDCA2 pos ) with no organised distribution pattern within healthy skin (3) .
The two populations of DC, MDC and PDC, can be distinguished by their ontogeny and their functional capacities. MDC are of myeloid origin whereas PDC could be of lymphoid origin (4) . The phenotypic characteristics of DC are presented in table 1.
MDC have functions of sentinels in peripheral tissues where they are resident and able to capture antigens. Regarding cutaneous compartments immature MDC are present in the skin under basal conditions in the dermis and in the epidermis (2) . MDC capture pathogenic agents, infected cells or degradation products using different methods (pinocytosis, phagocytosis…) through receptors that allow the capture of antigens and integrate the information provided by the pathological environment. They acquire a high level of maturation and migrate towards secondary lymphoid organs through the modulation of the expression of chemokine receptors: the decrease in the expression of CCR6 allows them for example to leave the skin, whereas an increased expression of CCR7 directs them towards lymph nodes. They also express HLA DR (Human Leukocyte Antigen, HLA) and co-stimulation molecules (CD40, CD80, CD83, CD86) that allow them to initiate a response from lymphocytes present in the lymph nodes (5) . MDC can induce a T helper type 1 (Th1) polarisation on CD4+ naive T lymphocytes leading to predominant secretion of IFN- by mature lymphocytes. They can also initiate a T helper type 2 (Th2) polarisation, lymphocytes secreting IL-4 and IL-5. A Th1 profile leads to a cellmediated immune response whereas a Th2 profile secondarily leads to the expansion and maturation of B lymphocytes into plasma cells and to a humoral response. The recruitment of CD8 pos naive T lymphocytes leads to their maturation into cytotoxic T lymphocytes that will cause lysis or induce apoptosis of infected cells via the perforin/granzyme and FAS (CD95)/FASLigand (CD95L) death inducing systems.
In a steady state, immature PDC are found in the blood, in T centers of lymphoid organs, in the thymus, in the tonsils and in lung tissue. The major role of PDC is a rapid response against virus aggressions. PDC have the peculiar capacity to produce large amounts of type I IFN in response to viral stimulation (4). The antigen capture potential of PDC is however less developed compared to other APC. Under basal state PDC are absent of the skin on the contrary to MDC, suggesting that the presence of PDC in the skin under pathological conditions is the consequence of active mechanisms of recruitment.
The trafficking of PDC in infectious, inflammatory or tumour context is not as well understood as MDC trafficking. Blood circulating PDC are able to reach inflammed lymph nodes by an hematogenous route across high endothelial venules (HEV). This recruitment mainly involves CD62L, CCR5 and ChemR23 (6) . PDC are absent of the afferent lymph which is in contrast with the trafficking pattern of MDC. High levels of PDC are found in inflamed skin, this recruitment could be mediated by ChemR23 (7) and CXCR3 (8) . Activated PDC observed in cutaneous lesions are capable of secreting large quantities of interferon  (IFN-) (4) . They can also stimulate naive T lymphocytes and induce Th1 or Th2 polarisation depending on the pathological context. Thereby the stimulation by viruses, by Toll-Like Receptors (TLR) 7 or 9 ligands will lead to a Th1 response whereas activation by IL-3 or CD40L will lead to a Th2 response.
Danger signals carried by pathogenic agents (PAMP) are recognised by TLR. MDC express TLR1, 2, 4, 5 and 8. PDC possess TLR 7 and 9. The expression of TLR7 is almost totally restricted to PDC (9) . Thereby MDC and PDC do not express the same set of TLR, but their expression is complementary and allows the recognition of a large panel of pathogenic motifs. We propose here an overview of dermatological diseases in which PDC are highly implicated and could bring new knowledges in physiopathology of some dermatoses or represent potential targets for new therapeutic approaches.
PDC and immunoallergic inflammatory cutaneous diseases
PDC were initially described in disorders involving an important lymphocytic infiltrate and were associated with the group of cutaneous pseudolymphomas. At the end of the 1980's a new cellular contingent termed plasmacytoid T cells or plasmacytoid monocytes was discovered in cutaneous lymphoid hyperplasias and in Jessner-Kanoff type lymphocytic infiltrates (10, 11) . Until then these cells had only been identified in reactive lymph nodes.
They were called plasmacytoid because their morphology was closed to the one of plasma cells with a developed endoplasmic reticulum. They also had common phenotypic characteristics with T lymphocytes and DC, considered to belong to Skin-associated Lymphoid Tissue (SALT) and their antigen presenting functions was a matter of debate (11) . In another study, the presence of plasmacytoid monocytes was established in 58% of biopsies removed from patients suffering from Jessner-Kanoff disease (75 biopsies) (12) .
It is now established that these plasmacytoid monocytes or plasmacytoid T cells that were described in the 1980's were actually PDC (13) .
Jessner Kanoff disease and lupus belong to the same spectrum of dermatosis that can be photoinduced. PDC are found in large quantities by immunohistochemistry in skin biopsies from patients suffering from chronic discoid lupus and lupus erythematosus (14) . PDC are preferentially distributed along the dermal-epidermal junction, around hair follicles and vessels. Cells positive for MxA (protein induced by IFN-α) are disseminated throughout the dermis and epidermis and their number correlates with the PDC density of the infiltrate. These data suggest that activated PDC secrete IFN-α (14) . PDC were also identified in lupic panniculitis lesions, a specific clinical type of lupus also known as lupus erythematosus profundus, in association with an important in situ secretion of IFN- (15) . The activation of PDC appears to occur via TLR 7 and 9 that recognise specific DNA and RNA sequences. In patients with lupus, there is a defect in the degradation of apoptotic cells leading to the accumulation of RNA and DNA fragments especially CpG enriched hypomethylated DNA fragments. These nucleic acid molecules generated by apoptotic cells can accumulate in the skin after exposure to ultraviolet rays (16) . In some patients, especially patients suffering from systemic lupus, anti-double stranded DNA antibodies and antibodies directed against nuclear antigens are produced. These antibodies lead to the formation of circulating immune complexes containing DNA. These immune complexes are able to activate the TLR9. It is now established that this activation occurs via the High Mobility Group Box protein type 1 (HMGB1), secreted by necrotic cells and inflammatory cells that binds to nuclear DNA present in the immune complex. HMGB1 will then interact with RAGE (receptor for advanced glycation end-products) which induces the activation of PDC via the TLR9-MyD88 pathway (17) . Recently, PDC have also been identified in lupus tumidus (spontaneous and photoinduced lesions) giving new arguments for a PDC recruitment after UV injury and supporting the concept of a PDC driven pathology in cutaneous lupus (18) .
Psoriasis is another inflammatory dermatosis in which hyperproliferation of keratinocytes is observed in response to an environmental aggression on a background of genetic predisposition. Understanding this disease comes down to determining how inflammatory cells of innate and adaptive immunity are capable of inducing the proliferation of keratinocytes and disorders of epidermal differentiation. The lymphocytic hypothesis is currently thought to be the most likely: autoreactive and constantly activated T lymphocytes produce cytokines that have pro-mitotic effects on keratinocytes (19) .
PDC have been identified in increased numbers in psoriasis skin lesions but are also present in the healthy skin of these same patients (20) . Within the lesions they are located in the dermis and have an activated phenotype. In parallel, the number of circulating PDC is reduced in these patients, which is in favour of a cutaneous recruitment. IFN-α produced by activated PDC is secreted during the early phase of the development of a psoriasis lesion and is transient. It induces a strong activation and expansion of pathogenic T lymphocytes. PDC and IFN-α are actors of innate immunity and appear to play a dominant role in the pathophysiology of psoriasis (20) . Blocking the secretion of IFN-α using an anti-BDCA2 monoclonal antibody inhibits the development of psoriasis lesions (experimental model of human psoriasis skin xenografts into mice) (20) .
Recently, the anti-microbial peptide LL37 has been identified as a key factor in the development and propagation of psoriasis lesions (21) . LL37 is highly expressed in psoriasis lesions and binds the self-DNA to form aggregated and condensed structures, that are potent activators of PDC. These complexes are delivered to the early endocytic compartment of PDC to trigger TLR9 and thereby IFN-α production (22) . The earliest event seems to be the conversion of Pro-chemerin into chemerin in psoriatic pre-lesionnal skin leading to the recruitment of ChemR23 expressing PDC. This Chemerin/ChemR23 axis is a new important player in the pathogenesis of psoriasis (23) .
Moreover, it has been described that the accidental application of a TLR-7 agonist, Imiquinod on psoriasis plaques could lead to its exacerbation and extension into guttate psoriasis (24) .
Lesions that had appeared at a distance from the application area excluded a simple Koebner phenomenon that could be secondary to the irritation caused by Imiquimod and PDC had been identified in psoriasis plaques. It would therefore be possible that PDC activated via the TLR-7 produce IFN-α in large quantities that could trigger psoriasis lesions.
The circulating contingent of PDC in patients suffering from atopic dermatitis is higher compared to control subjects resulting in a reduced MDC/PDC ratio. An inverse correlation was established between the ratio MDC/PDC and the clinical score of the disease (25) . The PDC infiltrate in atopic eczema lesions is less pronounced than in other inflammatory dermatoses such as psoriasis, contact eczema or lupus (26) . The rare PDC present in the skin are located in close proximity to vessels expressing a subtype of adressins, the peripheral neural adressins (PNAs). The PNAs are the physiological ligands of L-selectin (CD62L) which is strongly expressed by PDC (25) . PDC seem capable of promoting a Th2 immune response but also a Th1 response in synergy with MDC. This type of response profile was observed during the chronic phase of the atopic disease, enhancing the auto-maintenance of the disease.
Moreover, this weak recruitment of PDC in atopic eczema inflammatory lesions could explain the high sensitivity of the patients to viral infections, such as Human Herpes Virus (HSV)1 and HSV2 herpes viruses, pox-virus infections, favorized by a local deficiency in type I IFN (27) .
On the contrary, PDC have been found in large quantities in contact eczema lesions (26) .
Lichen planus is an inflammatory dermatosis with a yet undetermined etiology. Following the hypothesis of a viral origin, the genomes of different viruses were searched for in cutaneous biopsies. Cells infected by HHV-7 (Human-Herpes Virus 7) were identified significantly more frequently in lichen planus lesions than in healthy skin or in other inflammatory dermatoses (28) . A large number of PDC was also observed in dermal infiltrates in close proximity to the epidermal basement membrane. Within lesions, the DNA of HHV-7 was predominantly present in PDC expressing BDCA-2 and replicates within these cells. Clinical remission following treatment was associated with a decrease in viral DNA and in the number of PDC in situ (29) . Lichen planus could be associated with a reactivation of HHV-7, which prevalence is of roughly 90% within the general population, not following a cytopathogenic pattern, but as an intense inflammatory reaction initiated by PDC (29).
PDC and infectious disorders
PDC are in the front line in the antiviral immune response. Circulating and cutaneous PDC were analysed in a patient suffering from chicken pox, therefore infected with a Varicella Zoster Virus (VZV) (30) . PDC were identified in the epidermis and dermis and strongly expressed CXCR3. The circulating PDC contingent however was reduced. These data suggested that PDC probably left the peripheral blood circulation and were mobilised via CXCR3/CXCR3-ligand interactions on the site of the infection. They were activated and secreted IFN-α, as shown by the high number of MxA positive cells present in the dermis and epidermis.
PDC have also a crucial role in HSV1 and HSV2 infection. We have previously discussed the lack of PDC in atopic dermatitis skin as a factor for HSV surinfection. PDC participate in the immune control of recurrent HSV infection by their resistance to HSV infection and their capacity to induce a specific autologous T lymphocyte proliferation (31) .
PDC have also been identified in virally induced cancers, especially in cervical carcinomas induced by the Human Papilloma Virus (HPV) (32) . However, the role of PDC in the context of solid tumours remains unclear.
PDC in the context of malignant cutaneous disorders
The interactions of DC subsets with tumour cells and tumour micro-environment are complex and the function of DC is finally determined by a balance of several molecular interactions that regulate recognition, uptake, processing and presentation of tumour antigens (33) .
PDC have been identified within primary melanomas using immunohistochemical methods in a series including primary melanomas of different invasion stages, ranging from in situ melanoma to melanoma with Breslow index of 28mm (34) . PDC expressing CD123 were located around the tumour within a cellular infiltrate containing lymphocytes and MDC or in close proximity to blood vessels. More rarely, they are close to tumour cell clusters or directly in contact with melanoma cells. PDC have also been shown in cutaneous melanoma metastases. PDC are present in 79% of the malignant melanomas studied (42 primary tumours and 11 cutaneous metastases) whereas they were absent from samples of healthy skin and nevi that served as controls. Moreover, the analysis of 4 sentinel lymph nodes (1 lymph node with micrometastasis) revealed the presence of small clusters of PDC in these lymph nodes. In primary tumours and lymph nodes, the production of IFN-α was studied using the IFN alphainducible MxA protein. Results showed a weak production of IFN-α that could be linked to functional abnormalities and to a low level of maturation of PDC.
Another study showed the presence of PDC in primary melanoma at the periphery of tumour cells (5 tumours studied) (35) . The number of PDC was higher in invasive and metastatic melanoma than in in-situ tumours. In vitro, the functional study of PDC showed that they are capable of initiating a Th1 response with proliferation of CD8 pos T cells specifically directed against melanoma cells. The CD62L expression of these T cells allowed them to reach inflammatory skin. The supernatants of activated PDC also induced a strong expression of MHC I as well as CD95 on melanoma cells allowing their recognition and lysis by CD8 pos T cells. In vivo, however PDC had a weak level of activation. They were CD83 neg and produced very little amount of IFN-α. PDC were present in the tumour but at a sub-optimal level of activation that did not allow them to exhibit all their functional capacities.
In our laboratory, we were able to show the presence of PDC in different primary melanomas by immuno-histochemical staining of paraffin embedded tumour with the BDCA2 antibody ( fig 1) . PDC could also play a role in the phenomenon of regression that is histologically defined by the total or focal disappearance of malignant melanocytes in the dermis and/or epidermis.
Regression occurs in roughly 40% of primary melanomas (36) and can be considered as a localised phenomenon of autoimmunity as the T cell response that is observed is directed against tumour antigens that are considered as self-antigens. By analogy with autoimmune disorders such as cutaneous lupus, the potential role of IFN-α has been studied in the The role of PDC in melanoma can also be studied by looking at the effects of TLR ligands corresponding to the TLR expressed by PDC. Imiquimod, a synthetic agonist of TLR-7 that is specifically expressed by PDC, was tested in a murine model. One hundred and fifteen tumours induced by the intradermal injection of melanoma cells were studied (38) . Eighty nine tumours were treated with topical Imiquimod, with one application per day for 30 days, and 26 tumours were treated with the excipient. In Imiquimod-treated lesions, partial or complete regression was observed in 26% of cases, stabilisation was observed in 51% of cases and tumour evolution in 23% of cases. Characterisation of the inflammatory infiltrate following the application of Imiquimod showed a large number of PDC within the infiltrate. Therefore, the authors suggested that the anti-tumour effects of Imiquimod could be mediated by a massive recruitment of PDC, expressing TLR-7 and capable of producing IFN-α in situ.
In humans, no large study evaluated the effects of Imiquimod in the treatment of melanoma or associated cutaneous metastases. Few isolated cases showing the efficacy of Imiquimod on cutaneous melanomas in palliative therapy have been reported (39) (40) (41) . Only one study was performed on the use of Imiquimod as a first intention therapy for the treatment of 30 lentigo maligna that were not easily accessible through surgery (42) . Efficacy was shown in 93% of cases without any relapse at one year of follow-up. It is difficult to draw conclusions from this study, as the sample number was very reduced as the time of follow-up. A phase II multicentric study used a TLR9 agonist, PF-3512676, in the treatment of stage IV melanoma.
(M1a to M1c AJCC (43) ). Twenty patients were treated with weekly subcutaneous injections of 6mg of PF-3512676 over a period of 24 weeks. The disease progressed under treatment in 14 patients. Stabilisation was observed in 3 patients, and 2 patients partially responded (one of them benefited from a 140 weeks prolonged partial response). There were no severe side effects associated with this treatment. Follow-up of the phenotypic and functional modifications of PDC in the peripheral blood after 8 weeks of treatment showed an increase in the expression of HLA-DR and CD86 activation markers on PDC. A sustained induction of type I IFN expression was also found. These data demonstrate the possibility to act pharmacologically on PDC to activate them in vivo in order to fight against the tumour. The treatment with a TLR9 agonist was also proposed as an adjuvant treatment prior to extensive surgery of the primary melanoma and exeresis of sentinel lymph nodes (44) . In sentinel lymph nodes of treated patients, an activation of PDC, an increase in the production of proinflammatory cytokines and a decrease in the contingent of regulatory T cells have been observed (45) .
PDC are also present in basal cell carcinomas and have been studied as pharmacological targets of Imiquimod. PDC appeared to be recruited and activated in situ by Imiquimod, leading to the secretion of IFN-α within the tumour tissue (46) . The use of Imiquimod has been validated in the United-States and in Europe for the treatment of superficial basal cell carcinoma (47) . It has recently been shown that PDC were massively recruited in superficial basal cell carcinoma and acquired the expression of TRAIL during the application of topical Imiquimod. The expression of TRAIL Receptor 1 has been shown on the surface of basal cell carcinoma cells and a large number of tumour cells undergoing apoptosis were present in tumours treated with Imiquimod, suggesting that the activation of PDC by Imiquimod led to the apoptosis of tumour cells mediated by the TRAIL pathway (48) .
PDC have been identified in epidermoid carcinomas of the head and neck (49) . 
Hematological disorders with cutaneous expression involving PDC
PDC could play a crucial role in the occurrence of graft versus host disease (GVHD) following the allograft of hematopoietic stem cells as PDC have multiple functions and could play an active role in the phenomenon of tolerance. GVHD occurs when the donor's mature T cells recognise specific antigens of the recipient, which leads to the destruction of the recipient's cells. One study showed that chronic GVHD in humans was associated with a high level of PDC in the graft and in the recipients blood (51) . Data from a murine model suggested that PDC from the recipient prevented the occurrence of acute GVHD and enhanced the acceptance of the graft (52) .
PDC leukemia is an hematological disorder that has only recently been identified as a separate entity (53, 54) . This leukaemia was initially described as CD4 pos CD56 pos malignancy with skin manifestation but the high expression of CD123 marker was a strong argument for a Immuno-histochemical BDCA2 (Clone 104C12 Dendritics, Dardilly France) staining of a inflammatory regression area of a primary melanoma.
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Figure 2
Patient suffering from PDC leukemia. Cutaneous nodules of the trunk.
Figure 3
PDC of the GEN cell line after in vitro activation by influenza virus illustrating the typical morphology of virus activated PDC.
Figure 4
The role of PDC in various disease entities
